long-term effects of glp-1 receptor agonists The current significance and prospects for the use dual agonism GLP-1/Glucagon glp-1_analogs [TUSOM | Pharmwiki]

Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes

In summary, Arakawa M, et al

The title of this landmark paper was Preproglucagon Gene Expression in Pancreas and Intestine at the Level of Posttranslational Processing. However, the key finding was, It appears that GLP-I (1-37) may be a 'prohormone' or precursor for GLP-1 (7-37). This rather understated conclusion encapsulates the key discovery that ultimately made the revolutionary new treatments for metabolic disease possible

GLP-1 medicines in kidney inflammation The glucose lowering, hemodynamic benefits, and antiinflammatory actions of GLP-1 medicines may partly explain their efficacy in people with T2D and chronic kidney disease (CKD)

This translated into 12 fewer serious harm events per 1,000 GLP-1 users

111 Reduced production of pro-inflammatory cytokines, blocked NF-B signaling, and increased regulatory T-cell activity are some of the mechanisms through which GLP-1RA protects against intestinal inflammation in early-stage IBD models 112 (Figure 1)